Arca Biopharma, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Westminster Colorado United States (1992)

Organization Overview

First Clinical Trial
2003
NCT00073554
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ARCA Biopharma, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 2)

Arterial Occlusive Diseases (Phase 3)

Atrial Fibrillation (Phase 2)

Atrial Flutter (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Coronary Disease (Phase 2)

Heart Diseases (Phase 2)

Heart Failure (Phase 2)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Stroke (Phase 2)

Thrombosis (Phase 3)

Vascular Diseases (Phase 2)

Venous Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 7